Icotinib in Advanced Metastatic Patients With NSCLC Previously Treated With Chemotherapy

Inclusion Criteria: * Histologically or cytologically confirmed locally advanced/metastatic (stage IIIB/stage IV, using the American Joint Committee on Cancer \[AJCC\] 6th edition of tumor-node-metastasis \[TNM\] staging system) NSCLC patients * Progressed after at least one platinum-based chemotherapy regimen at entry * Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2 * At least one measurable lesion by Response Evaluation Criteria in Solid Tumors version 1.0 * Adequate hematologic and biochemical values Exclusion Criteria: * Patients with symptomatic brain metastases * Malignant tumor within the previous five years * Severe infection; congestive heart failure * Previous treatment with drugs targeting EGFR * History of interstitial lung disease